Peripheral blood cfDNA detection using clonoSEQ assay in multiple myeloma is concordant with bone marrow and clinical biomarkers
A blood test for myeloma patients shows promise for replacing painful bone marrow biopsies, though larger studies are needed to confirm.
In a Maya Clinic cohort of multiple myeloma patients, peripheral blood cfDNA detected by the clonoSEQ assay was concordant with bone marrow MRD status and clinical biomarkers, suggesting liquid biopsy-based monitoring could reduce the need for invasive bone marrow biopsies. This is a letter-format publication; findings are preliminary and require prospective validation in larger cohorts.
What the study was
- Study design
- Concordance analysis (observational, single-institution)
- Population
- Multiple myeloma patients (Mayo Clinic)
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Blood Cancer Journal
Why it surfaced
Demonstrates peripheral blood cfDNA concordance with bone marrow MRD in myeloma; clinically useful signal for liquid biopsy monitoring. Letter format limits scoring (design cap) and classification confidence reduced accordingly.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.